Hanover, MA, United States of America

Erik Devereaux

USPTO Granted Patents = 3 

Average Co-Inventor Count = 11.3

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Erik Devereaux

Introduction

Erik Devereaux is a notable inventor based in Hanover, MA (US). He has made significant contributions to the field of cancer treatment through his innovative work in antibody compositions. With a total of 3 patents to his name, Devereaux is recognized for his dedication to advancing medical science.

Latest Patents

Among his latest patents are two key inventions related to anti-CD39 antibodies. The first patent, titled "Anti-CD39 antibody compositions and methods," provides compositions that can be used in treating cancer. The second patent, "Antibodies that bind CD39 and uses thereof," relates to anti-CD39 antibodies and their applications in cancer treatment. These inventions highlight his commitment to developing effective therapies for serious health conditions.

Career Highlights

Erik Devereaux is currently employed at Surface Oncology, Inc., where he continues to work on groundbreaking research in oncology. His role at the company allows him to collaborate with other experts in the field and contribute to the development of innovative cancer treatments.

Collaborations

Devereaux has worked alongside talented colleagues, including Scott C Chappel and Andrew Lake. Their combined expertise fosters a collaborative environment that enhances the potential for groundbreaking discoveries in cancer research.

Conclusion

Erik Devereaux's contributions to the field of cancer treatment through his patented inventions demonstrate his innovative spirit and commitment to improving patient outcomes. His work at Surface Oncology, Inc. continues to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…